Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)

Buti, MariaStepanova, TatjanaCelen, Mustafa K.Flisiak, RobertRyder, Stephen D.Streinu-Cercel, AdrianGurel, Selim2024-04-242024-04-2420170270-91391527-3350https://hdl.handle.net/11468/2311468th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting -- OCT 20-24, 2017 -- Washington, DC[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)Conference Object66488A488AWOS:000412089801057Q1